Refractory anemia with excess blasts (RAEB)

Antonio Cuneo, Gianluigi Castoldi

Hematology Section, Department of Biomedical Sciences, University of Ferrara, Corso Giovecca 203, Ferrara, Italy (AC, GC)

Published in Atlas Database: November 2003
Online updated version: http://AtlasGeneticsOncology.org/Anomalies/RAEBID1105.html
DOI: 10.4267/2042/38053

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2004 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Alias: RAEB-1 and RAEB-2

Note: This disorder is part of the heterogeneous category of myelodysplastic syndrome (MDS). According to the FAB classification of MDS, RAEB includes those patients with 5-20% blasts in the bone marrow (BM). Because the severity of the disease largely depends on the percentage of blasts in the BM, two categories of RAEB were recognised by the WHO classification, i.e. RAEB-1 and RAEB-2, with 5-9% and 10-19% blasts, respectively.

In this card, the FAB classification will be used, because the majority of available data on cytogenetic anomalies was derived from studies published before WHO classification.

Clinics and pathology

Phenotype/cell stem origin

RAEB is a clonal disorder originating from a totipotent stem cell or from a multipotent myeloid progenitor cell, characterized by ineffective hemopoiesis and dyserythropoiesis. The blast cells present in the BM are usually CD34+ and express myeloid markers (i.e. CD33 and/or CD13).

Epidemiology

There are few data on the epidemiology of RAEB, which may account for 20-30% of all MDS cases. MDS is predominantly diagnosed in the elderly population. The global incidence of all MDS was comprised between 3.5 and 12.6 new cases / year / per 100,000 in some studies. The incidence may rise from 0.5 MDS cases per year in the 40 years age-group to 89 cases per year in the >80 age-group.

Clinics

RAEB usually presents with hypercellular bone marrow (BM) with 5-20% blasts (5-9% in RAEB-1 and 10-19% in RAEB-2) and cytopenias of various degree. Blast cells (<20%) can be present in the peripheral blood.

The patient may be asymptomatic or, alternatively he/she may suffer from BM failure-related symptoms.

Cytology

Criteria for the recognition of dysplastic features of BM cells were published by the FAB group. Dyserythropoiesis includes megaloblastoid changes of erythroid precursors, multinucularity, nuclear fragmentation, unstained area in the cytoplasm (dysemoglobinization). Dysgranulocytopoiesis include hypogranular neutrophils, the pseudo-Pelger anomaly of neutrophils. Micromegakaryocytes, large mononuclear forms and multiple separated nuclei are major signs of dysmegakaryocytopoiesis.

Pathology

The bone biopsy may be useful in some cases of MDS with BM fibrosis and allows for the demonstration of the so called "abnormal localization of immature precursors" (ALIP) which may represent a prognostic factor.

Treatment

Treatment of this condition in the elderly patient is largely supportive, including blood transfusion in patients with symptomatic anemia. Anemic patients with low serum erythropoietin (EPO) levels may benefit from the administration of rHu-EPO. Low dose cytarabine can be used to reduce the burden of blasts. Myeloablative regimens including anthracyclines and cytarabine in conventional or high doses can be used in
high-risk patients under 60 years. Allogeneic bone marrow transplantation may offer a chance of cure in young patients.

**Evolution**
This is an oligoblastic leukemia, carrying a 20-40% probability of evolving into leukemia. In a study approximately 25% of the patients developed acute myeloid leukemia (AML) within 18 months. The probability of RAEB to transform into AML is lower in the RAEB-1 group (approximately 50% of the patients develop acute leukemia within 6 years) than in the RAEB-2 group (approximately 50% at 18 months with overt leukemia).

**Prognosis**
Median survival of RAEB falls in the 1-2 year range. The best outcome is usually observed in RAEB-1. Chromosomal abnormalities have independent prognostic significance and are to be included in risk assessment at diagnosis. Favourable cytogenetic features are normal karyotype, 5q- or 20q- isolated; unfavourable features are complex karyotype (i.e. 3 or more clonal anomalies) and abnormalities of chromosome 7q; other abnormalities identify patients in the intermediate cytogenetic-risk group.

**Cytogenetics**

**Cytogenetics morphological**
There is no specific chromosome marker for patients with RAEB, up to 60% of whom may show an abnormal karyotype. More sensitive techniques such as fluorescence in situ hybridization (FISH) found that a minority of patients with apparently normal karyotype can be shown to carry an occult chromosome defect. The 5q- chromosome may be found in up to 40% of the cases, usually in association with additional chromosome aberrations. Approximately 20% of the cases may carry a `-7/7q- or trisomy 8. A chromosome 12p deletion or 11q deletion can be found in 5% of cytogenetically abnormal cases. Those patients with a 17p deletion may display distinctive hematologic features, including dysgranulopoiesis with the pseudo-Pelger anomaly and small vacuoles in the cytoplasm of the neutrophils, p53 mutation and poor outcome. A number of very rare chromosome aberrations were described in some reports. Recurrent deletions are represented by del(3)(p14p21), del(6)(p21), del(9)(q13q22), del(12)(p13), del(18)(p11). Monosomy Y may occur more frequently in elderly males. Rare recurrent structural anomalies which can also be found in acute myeloid leukemia include: t(6;9)(p23;q34); t(3;5)(q25;q35); t(1;13)(p36q21); t(3;21)(q26;q22); inv(3)(q21q26); t(7;11)(p15;p15). Trisomies are represented in <1% of the cases by +4; +11; +13; +21.

**References**


This article should be referenced as such: